Investigation for mechanism of onset of thymic epithelial tumors with special reference to possible viral involvement
Project/Area Number |
17K10812
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory surgery
|
Research Institution | Kansai Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
齊藤 朋人 関西医科大学, 医学部, 講師 (10548605)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 縦隔外科 / 胸腺上皮性腫瘍 / 胸腺癌 / ウィルス / 網羅的遺伝子解析 |
Outline of Final Research Achievements |
In this study, we tried to reveal mechanism of onset of thymic epithelial tumors with special reference to possible viral involvement using comprehensive mRNA expression profiling of 770 immune-related genes. Contrary to our expectation, no direct involvement of viral infection could be detected. However, we found that PRAME (Preferentially expressed antigen in melanoma) was specifically expressed in thymic squamous cell carcinoma, whereas thymomas displayed negative expression or focal and weak expression. These results identified PRAME as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma.
|
Academic Significance and Societal Importance of the Research Achievements |
胸腺上皮性腫瘍の発症にウィルスが関与していることの証明は当初の期待とは異なり、本研究では直接的な証明はできなかった。 しかしながらPRAMEが胸腺癌特異的マーカーであり、免疫組織化学染色で既知の鑑別マーカーであるCD5やCD117と組み合わせることで胸腺癌のより正確な診断に有用であることが証明された。 胸腺癌と胸腺腫の鑑別診断は時に困難であることが知られており、PRAMEの免疫染色により鑑別診断制度を高め、ひいては治療選択に貢献できる可能性が本研究から示唆された。今後症例を蓄積しPRAMEのマーカーとしての有効性を検証していく必要がある。
|
Report
(4 results)
Research Products
(25 results)
-
-
-
-
-
-
-
[Journal Article] Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.2018
Author(s)
Saito T, Tsuta K, Ishida M, Ryota H, Takeyasu Y, Fukumoto KJ, Matsui H, Taniguchi Y, Yanagimoto H, Kurata T, Murakawa T.
-
Journal Title
Lung Cancer.
Volume: 125
Pages: 230-237
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Combined small cell lung carcinoma and giant cell carcinoma: a case report.2017
Author(s)
Saito T, Tsuta K, Fukumoto KJ, Matsui H, Konobu T, Torii Y, Yokoi T, Kurata T, Kurokawa H, Uemura Y, Saito Y, Murakawa T.
-
Journal Title
Surg Case Rep.
Volume: 3(1)
Issue: 1
Pages: 52-52
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
[Presentation] Comparison Study of PD-L1 Immunohistochemistry Assays with 22C3 and 28-8: Analysis on Surgical Specimens of NSCLC.2017
Author(s)
Saito T, Tsuta K, Ishida M, Ryota H, Takeyasu Y, Fukumoto J, Matsui H, Taniguchi Y, Yanagimoto H, Yokoi T, Kurata T, Murakawa T
Organizer
18th World Conference on Lung Cancer
Related Report
-
-
-
[Presentation] Clinical and pathological characteristics of spontaneous pneumothorax in women: a 25-year single-institutional experience.2017
Author(s)
Saito T, Saito Y, Fukumoto KJ, Matsui H, Nakano T, Taniguchi Y, Kaneda H, Konobu T, Sakaida Nm Okamura A, Uemura Y, Tsuta K, Murakawa T
Organizer
CHEST Annual Meeting 2017
Related Report
-
-
-